Search Results
6 Results Found for “zongertinib”
This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging ...
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide.1Â Over the past two decades, the molecular characterization of NSCLC has transformed the therapeutic landscape by enabling the development of targeted therapies that have significantly improved outcomes ...
At WCLC 2025, final FLAURA2 results revealed that osimertinib plus chemotherapy significantly improves overall survival in EGFR-mutant advanced non-small cell lung cancer (NSCLC), extending median survival to nearly four years. Experts stress the practice-changing impact, while highlighting the importance of tailoring treatment to patient fitness, comorbidities, and individual goals.
Dr Federico Monaca discusses the role of consolidative thoracic radiotherapy after chemo-immunotherapy in ES-SCLC, highlighting improved chest control but uncertain survival impact. He also reflects on key WCLC 2025 updates, including DLL3-targeted therapies, novel immunotherapy combinations, and biomarker-driven strategies offering fresh hope in small cell and non-small cell lung cancers.
Dr Igor Gómez-Randulfe discusses new real-world evidence on second-line carboplatin plus pemetrexed after osimertinib in EGFR-mutant NSCLC. The retrospective analysis highlights modest response rates and short overall survival, reinforcing the need for more effective strategies and raising critical questions about sequencing, intensification, and resistance profiling.
The US Food and Drug Administration (FDA) has granted Priority Review for its New Drug Application (NDA) for zongertinib (BI 1810631), a treatment for adults with advanced non-small cell lung cancer (NSCLC) characterized by HER2 (ERBB2) mutations who have undergone prior ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
